Based on the view of effective risk reduction, we spotted the data from a multicenter study from America suggesting that exposure to anti-TNFα agents in UC patients is associated with a reduction in CRC risk after adjustment for possible confounding factors (OR 0.78, 95% CI 0.73–0.83, p < 0.0001) [14], which was confirmed in other studies additionally [178,179]. This evidence concerns the gene TNF and colorectal carcinoma.